Abstract
Treatment of knee osteoarthritis (OA) remains a challenging concern. Preclinical studies provided accumulating evidence on resveratrol efficacy in ameliorating degenerative articular damage. The present study was conducted to evaluate the effects of resveratrol as monotherapy on the serum level of type II collagen (Coll 2-1) and aggrecan in patients with knee osteoarthritis. The study was an open-labeled noncontrolled clinical trial. Resveratrol 500 mg/day in a single oral dose was given to the patients with knee osteoarthritis for 90 days. The serum levels of Coll-2-1, aggrecan, and biomarkers of inflammation were measured pre- and posttreatment. Hematological profiles and both hepatic and renal function markers were investigated at the baseline and at the end of the treatment for evaluating the tolerability and safety of resveratrol. Visual Analog Scale (VAS) for pain and Knee injury and Osteoarthritis Outcome Score (KOOS) for disease activity were clinically assessed monthly. Administration of 500 mg resveratrol for three months led to a nonsignificant decrease in the serum level of Coll 2-1 while a significant increase in aggrecan serum level. Resveratrol significantly improves pain score measured by VAS and KOOS after 30 days. Improvements in patients' activity and functional status were also evident at day 30 and kept on for three months which was reflected by KOOS subscale scores and with a significant improvement in all KOOS areas. In conclusion, oral administration of resveratrol as a monotherapy provides a remarkable improvement in the clinical status of the patients but has no significant effect on serum levels of Coll 2-1.
Highlights
Knee osteoarthritis (OA) is a complex degenerative articular disorder that is described by the degeneration of articular cartilage, mostly proteoglycans, resulting in damage of articular tissue and hypocellular outcome that leads to impair joint function [1]
Clinical trials that explore the efficacy of resveratrol monotherapy in joint disorder such as OA through investigating cartilage-derived molecules are obscure to date
The principal findings of the current study suggest that oral administration of resveratrol as monotherapy for three months could improve knee pain, OA symptoms, stiffness, patient activity, clinical status, and quality of life which has been reflected by Knee injury and Osteoarthritis Outcome Score (KOOS) subscale scores and Visual Analog Scale (VAS) scale for pain
Summary
Knee osteoarthritis (OA) is a complex degenerative articular disorder that is described by the degeneration of articular cartilage, mostly proteoglycans, resulting in damage of articular tissue and hypocellular outcome that leads to impair joint function [1]. Resveratrol, trans3,5,4-trihydroxystibene, is a natural phytoalexin derived from Polygonum cuspidatum; it is found in high concentration in the grape skin, cranberries, and peanuts. It is considered as a rational herbal candidate with a potential therapeutic interest in joint disorder; it shows pleiotropic effects. Clinical trials that explore the efficacy of resveratrol monotherapy in joint disorder such as OA through investigating cartilage-derived molecules are obscure to date
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
